About Us

ONO PHARMA USA is a pharmaceutical company dedicated to bringing patients innovative medicines across oncology, immunology, neurology, and specialty.

Always Innovative. Always ONO.

ONO PHARMA USA was established in 1998 as the United States subsidiary of ONO PHARMACEUTICAL CO., LTD., a pharmaceutical company founded in Osaka, Japan in 1717. Throughout our history, we have been dedicated to developing novel therapeutics that benefit patients. Our U.S. headquarters are in Cambridge, Mass., an exciting global hub of biotech and biopharmaceutical innovation.

Mission and Values

Dedicated to the Fight Against Disease and Pain

Our philosophy captures our longstanding commitment to addressing the most pressing issues in healthcare. ONO is dedicated to advancing medicines that will have meaningful impact on patients, their families, the healthcare system, and wider society.

Our Vision

Be passionate challengers. We wholeheartedly embrace challenges and are fueled by unwavering determination as we harness our unique strengths to develop groundbreaking pharmaceuticals for patients.

Our Values

  • ONO aims to be a world-changing team:
    We tackle healthcare challenges that haven’t yet been solved. To do this, we work as an integrated team, bringing together our wisdom, heart, aspirations, and strengths.
  • The greater the challenge, the more passionately ONO will rise to meet it:
    We will inevitably come up against roadblocks as we undertake important challenges. When we encounter obstacles, we always approach them with ingenuity and follow through with perseverance.
  • ONO acts with dignity and pride:
    We should never lose the commitment, dedication, and pride we feel working in the pharmaceutical industry. Our goal is to bring hope to those around the world who are waiting for us to deliver solutions.
ONO employee researching impactful medicines

Guided by ONO’s Global Code of Conduct

Corporate Social Responsibility (CSR)

As part of our commitment to bringing effective therapies to patients who need them, ONO is active in a number of initiatives to support societal and environmental health.

Corporate Social Responsibility
  • As part of our ECO VISION 2050 plan, we are working toward zero greenhouse gas emissions and 100% renewable energy by 2035.
  • To improve access to healthcare globally, we work with partners to provide resources to geographies that lack sufficient access.
  • Through partnerships with NPOs and NGOs, we provide support for medical education, including professional training, in developing countries.

We are always on the lookout for additional opportunities to work on these issues, and we welcome partnerships with organizations who have a similar mission.

Get in Touch With Us

Legacy

ONO Through the Centuries

From an apothecary in 1717 to a global biopharmaceutical company that has helped change treatment paradigms, ONO has been dedicated to developing innovative therapies for patients for more than 300 years.

1717
Planting ONO’s Roots

20-year-old Ichibei Fushimiya I founds an apothecary in Osaka, with the help of his mentor. This local business, named Fushimiya Ichibei, would one day grow into ONO.

Year 1717
1878
The Rise of Pharmaceuticals

The beginning of the Meiji era brought a new interest in Western medicines. A man named Ichibei Ono, 7th generation, constructed a new shop in Doshomachi, Osaka, where ONO was originally founded.

Year 1878
1934
Incorporation of the Ono Name

Ichibei Ono VIII reorganizes the company and changes the name from Fushimiya Ichibei to Ono Ichibei Shoten. It expands into drug manufacturing and begins exploring drug development.

Year 1934
1948
Post-World War II Expansion

ONO PHARMACEUTICAL Co., Ltd. is established by Ichibei Ono IX (Yuzo Ono) and expands into the over-the-counter market.

Year 1948
1968
Pioneering Prostaglandin Research

ONO is the first company to achieve full prostaglandin synthesis, laying the groundwork for a range of innovative therapeutics.

Year 1968
1998-2014
ONO’s Global Expansion

To expand the company’s global reach, in 1998, ONO PHARMA UK and ONO PHARMA USA are established. In 2013 and 2014, respectively, ONO PHARMA Korea and Taiwan are established.

Year 1998
2014
Advances in Cancer Immunotherapy

The world’s first anti-PD-1 antibody, nivolumab, is approved by the FDA. Developed by ONO and Kyoto University, this novel strategy for fighting cancer has changed the treatment paradigm for patients across the globe.

Year 2014
2020
Expansion in the U.S.

Kunihiko Ito, MBA appointed as CEO of ONO PHARMA USA to help expand the company’s work in the U.S.

Year 2020
2021
Relocation of U.S. Headquarters

ONO PHARMA USA moves its U.S. headquarters from New Jersey to Cambridge, Mass., a global hub of biopharmaceutical and biotech innovation.

Year 2021
2023
Poised to Grow

ONO PHARMA USA continues to expand its R&D initiatives and commercial capabilities. In the U.S., ONO is currently carrying out clinical trials to investigate potential therapies in two of our focus areas: oncology and neurology.

Year 2023
Leadership Team

Meet Our Leaders

Our team of diverse and accomplished leaders come from many professional backgrounds, but have a common goal – to bring innovative medicines to patients who need them.

See what it’s like to Work@ONO

Kunihiko Ito, MBA
Kunihiko Ito, MBA
President / CEO
Mitsunobu Tanimoto
Mitsunobu Tanimoto
EVP, U.S. Head of Clinical Development
David Trexler
David Trexler
Chief Commercial Officer
Daniel Moynihan
Daniel Moynihan
General Counsel
Donna Supko, Ph.D.
Donna Supko, Ph.D.
VP, Regulatory Affairs
Howard Fingert, M.D., FACP
Howard Fingert, M.D., FACP
VP, Medical - Oncology
U. Shivraj Sohur, M.D., Ph.D.
U. Shivraj Sohur, M.D., Ph.D.
VP, Medical - Neurology
Thomas Lechner, MSc. Ph.D.
Thomas Lechner, MSc. Ph.D.
VP, Medical Affairs
Archana Sondhi
Archana Sondhi
VP, Sales & Marketing
Raymond Frost
Raymond Frost
VP, Market Access
Charles Schmidheiser
Charles Schmidheiser
VP, business operations
Sarala Gudiwada, MBBS, MPH
Sarala Gudiwada, MBBS, MPH
VP, Drug Safety and Pharmacovigilance
Ralph Monaghan
Ralph Monaghan
VP, Quality Assurance
Our Offices

Global Innovation

ONO is growing and now has 20 locations across five countries around the world. Most of our research and development (R&D) takes place in Osaka, Japan, the company’s original location, but we are quickly expanding our R&D efforts in other locations, including the U.S.

World Map
Get in touch to learn more.
Explore what it’s like to work at ONO PHARMA USA.